44 articles - From Saturday Mar 05 2022 to Friday Mar 11 2022
Guidelines, position statements, white papers, technical reviews, consensus statements, etc…
| Arthritis Care Res (Hoboken) |
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and use of echocardiography in patients with suspected or confirmed KD. |
| Arthritis Rheumatol |
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and use of echocardiography in patients with suspected or confirmed KD. |
meta-analyses and systematic reviews
| Rheumatology (Oxford) |
A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic medications (DMARDs) in-utero. Most evidence for clinically harmful effect was for early administration of the BCG vaccine to infants exposed in-utero to TNF inhibitors with high transplacental transfer rates. |
AA Amyloidosis complicating cryopyrin-associated periodic syndrome: a study on 86 cases including 23 French patients and systematic review. AA amyloidosis can occur in nearly al CAPS subtypes. Interleukin-1 inhibitors are effective, underlining the necessity of an early diagnosis of CAPS in order to start this treatment as soon as possible among AA-CAPS patients. |
RCT, clinical trials, retrospective studies, etc…
| Ann Rheum Dis |
2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases. These recommendations cover a range of lifestyle behaviours and can guide shared decision making between people with RMDs and health professionals when developing and monitoring treatment plans. |
Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Mavrilimumab plus 26 |
Osteoarthritis endotype discovery via clustering of biochemical marker data. This work supports the existence of differential phenotypes in OA. The biomarker approach could potentially drive stratification for OA clinical trials and contribute to precision medicine strategies for OA progression in the future. |
Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial. Biomarker-guided strategies of therapy withdrawal are feasible in clinical practice. This study demonstrates that using predictive markers of subclinical inflammation is a promising tool in the decision-making process of therapy withdrawal, which translates into direct benefit for patients. |
| Arthritis Care Res (Hoboken) |
A Personalized Risk Model Leverages MRI-based Structural Phenotypes and Clinical Factors to Predict Incidence of Radiographic Osteoarthritis. Four ROAMES phenotypes may contribute to time to radiographic OA incidence and if validated could be used as promising tool for personalized OA management. |
Effects of weight change on knee and hip radiographic measurements and pain over 4 This large, longitudinal study (n=2752 with 4-year follow-up) suggests that weight loss may protect against, and weight gain may exacerbate radiographic and symptomatic knee OA, while weight change (5% threshold) does not have significant effects on hip OA. |
Proton Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition in a Population-Based Study. In this study using real-world data, incident use of PPIs was not associated with a higher risk of CPPD compared with incident H2 blocker use, although use of PPI and H2 blockers had higher risk compared to non-use. |
The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) is Associated with Damage In Systemic Lupus Erythematosus Patients. The SLICC-FI is associated with damage accrual in SLE patients from a multi-ethnic cohort, supporting the importance of this index in the evaluation of SLE patients, combining several aspects of their disease. |
| Arthritis Res Ther |
A machine learning-assisted model for renal urate underexcretion with genetic and clinical variables among Chinese men with gout. A prediction model for RUE composed of four SNPs and readily accessible clinical features was established with acceptable accuracy for men with gout. |
Amniotic suspension allograft improves pain and function in a rat meniscal tear-induced osteoarthritis model. In this study, an injection of ASA was well tolerated with no adverse events. Improvements in pain and function, along with cartilage properties at day 10, were observed. Increases in anti-inflammatory cytokines was also seen, along with no significant cartilage degeneration at day 21 compared to the vehicle control. This study provides evidence for the use of ASA as a nonsurgical treatment for knee OA. |
Angiopoietin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica. This study, performed in two independent international cohorts, consistently shows the potential of angiopoietin-2/-1 ratios and MMP-3 levels to identify GCA in patients presenting with PMR. These biomarkers may be used to select which PMR patients require further diagnostic workup. Platelet counts may be used to discriminate GCA from GCA look-alike patients. |
Prediction of knee osteoarthritis progression using radiological descriptors obtained from bone texture analysis and Siamese neural networks: data from OAI and MOST cohorts. The proposed combined model provides a good performance in the prediction of mJSN over 4 to 6 years in patients with relevant KOA. Furthermore, the current study presents an important contribution in showing that TBT-based OA prediction models can work with different databases. |
Single-cell transcriptomics of popliteal lymphatic vessels and peripheral veins reveals altered lymphatic muscle and immune cell populations in the TNF-Tg arthritis model. Single-cell RNA-seq can be used to investigate functional genomics of lower limb vasculature in mice. Our findings confirm the inflammatory transcriptome of TNF-Tg vessels and altered gene expression in SMC populations. This study further supports a potential role of mesenchymal stromal cells in inflammatory-erosive arthritis pathogenesis, and warrants future studies to define the effects of this TNF-altered transcriptome on PLV function and joint homeostasis. |
| Arthritis Rheumatol |
Association of Cardiac Biomarkers with Cardiovascular Outcomes in Patients with Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study. In patients with PsD, cTnI may reflect the burden of atherosclerosis, independent of traditional CV risk factors. cTnI and NT-proBNP are associated with incident CV events independent of the FRS, however, further study of their role in CV risk stratification is warranted. |
Five-Year Structural Changes in Patients with Meniscal Tear and Osteoarthritis: Data from an RCT of Arthroscopic Partial Meniscectomy vs. Physical Therapy. These findings suggest the association between APM and MRI-based changes is most apparent in the 18 months after surgery. The reason for the attenuation of this association over longer follow-up merits further investigation. |
Glutaminase 2 Promotes Interleukin-2 Production in CD4+ T cells by Supporting Antioxidant Defense. Our findings suggest that GLS2 has a crucial role in IL-2 production by CD4 + T cells by supporting the antioxidant defense and offer a new approach to correct IL-2 production by T cell in SLE. |
IL-2-related regulatory CD4 T-cell deficiency leads to the development of lung fibrosis and vascular remodeling. Immunotherapies aiming at restoring Treg-cell homeostasis could be relevant in SSc. An intervention based on low-dose IL-2 injections, as already proposed in other autoimmune diseases, could be the most suitable modality for future developments. |
| Rheumatology (Oxford) |
Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan. Our findings suggest potential benefits of prolonged tocilizumab use in dcSSc patients. The discontinuation of tocilizumab can lead to the progression of skin and visceral manifestations. Tapering rather than the discontinuation of tocilizumab is a viable option in dcSSc patients who experience remarkable clinical improvement. |
Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab. Obinutuzumab appears to be effective and steroid-sparing in renal and non-renal SLE patients with secondary non-response to rituximab. These patients have severe disease with few treatment options but given responsiveness to B cell depletion, switching to humanised type-2 anti-CD20 therapy is a logical approach. |
Increased risk of rheumatoid arthritis in patients with endometriosis: genetic aspects. Epidemiological data has suggested a link between endometriosis and risk of incident RA. The similarities between molecular and cellular pathways of endometriosis and RA may implicate a partially shared genetic background. In this review, we present an overview of the shared genetic factors known thus far, which are associated with the development of both disorders. |
Temporal Trends in COVID-19 outcomes in People with Rheumatic Diseases in Ireland: data from the COVID-19 Global Rheumatology Alliance registry. No temporal trend was observed in either COVID-19 related hospitalisation or mortality outcomes for people with rheumatic disease in Ireland. |
The role of comorbidities alongside patient and disease characteristics on long-term disease activity in RA using UK inception cohort data. This study demonstrates an association between sociodemographic and clinical factors and long-term RA disease activity, in models adjusting for comorbidity burden. The findings call for more holistic and targeted patient management in patients with RA and provide insights for more individualised management plans even on first presentation to rheumatology. |
Treatment of childhood-onset Takayasu arteritis: switching between anti-TNF and anti-IL-6 agents. In conclusion, both TNF-a and IL-6 inhibitors are effective alternatives in treating patients with childhood-onset TA. However, prospective randomized controlled trials are needed for the comparison of their effectiveness. |
Plenty of the editorials are available as full text through the publisher website using the provided link
Letters to the editors and authors’ replies
| Arthritis Rheumatol |
all remaining publications eg case reports, images of the month, etc…
| Arthritis Rheumatol |
| Rheumatology (Oxford) |